Literature DB >> 15164072

Moving towards individualized medicine with pharmacogenomics.

William E Evans1, Mary V Relling.   

Abstract

Individuals respond differently to drugs and sometimes the effects are unpredictable. Differences in DNA that alter the expression or function of proteins that are targeted by drugs can contribute significantly to variation in the responses of individuals. Many of the genes examined in early studies were linked to highly penetrant, single-gene traits, but future advances hinge on the more difficult challenge of elucidating multi-gene determinants of drug response. This intersection of genomics and medicine has the potential to yield a new set of molecular diagnostic tools that can be used to individualize and optimize drug therapy.

Mesh:

Year:  2004        PMID: 15164072     DOI: 10.1038/nature02626

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  157 in total

1.  Delivering a pharmacogenetic service: is there a role for genetic counselors?

Authors:  Alice Callard; William Newman; Katherine Payne
Journal:  J Genet Couns       Date:  2011-11-04       Impact factor: 2.537

Review 2.  Chinese medicine pattern diagnosis could lead to innovation in medical sciences.

Authors:  Ai-Ping Lu; Ke-Ji Chen
Journal:  Chin J Integr Med       Date:  2011-11-06       Impact factor: 1.978

Review 3.  [Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].

Authors:  J C Stingl; K S Just; K Kaumanns; M Schurig-Urbaniak; C Scholl; D von Mallek; J Brockmöller
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

4.  Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium.

Authors:  Niloufar Farzan; Susanne J Vijverberg; Anand K Andiappan; Lambang Arianto; Vojko Berce; Natalia Blanca-López; Hans Bisgaard; Klaus Bønnelykke; Esteban G Burchard; Paloma Campo; Glorisa Canino; Bruce Carleton; Juan C Celedón; Fook Tim Chew; Wen Chin Chiang; Michelle M Cloutier; Denis Daley; Herman T Den Dekker; F Nicole Dijk; Liesbeth Duijts; Carlos Flores; Erick Forno; Daniel B Hawcutt; Natalia Hernandez-Pacheco; Johan C de Jongste; Michael Kabesch; Gerard H Koppelman; Vangelis G Manolopoulos; Erik Melén; Somnath Mukhopadhyay; Sara Nilsson; Colin N Palmer; Maria Pino-Yanes; Munir Pirmohamed; Uros Potočnik; Jan A Raaijmakers; Katja Repnik; Maximilian Schieck; Yang Yie Sio; Rosalind L Smyth; Csaba Szalai; Kelan G Tantisira; Steve Turner; Marc P van der Schee; Katia M Verhamme; Anke H Maitland-van der Zee
Journal:  Pharmacogenomics       Date:  2017-06-22       Impact factor: 2.533

5.  Label-free molecular imaging of atherosclerotic lesions using multimodal nonlinear optical microscopy.

Authors:  Thuc T Le; Ingeborg M Langohr; Matthew J Locker; Michael Sturek; Ji-Xin Cheng
Journal:  J Biomed Opt       Date:  2007 Sep-Oct       Impact factor: 3.170

6.  Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?

Authors:  Phuong Thu Vu Hoang; Jérôme Ambroise; Anne-France Dekairelle; Jean-François Durant; Valentina Butoescu; Vu Luan Dang Chi; Nghia Huynh; Tan Binh Nguyen; Annie Robert; Christiane Vermylen; Jean-Luc Gala
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 7.  Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.

Authors:  Janneke P C Grutters; Mark Sculpher; Andrew H Briggs; Johan L Severens; Math J Candel; James E Stahl; Dirk De Ruysscher; Albert Boer; Bram L T Ramaekers; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

8.  Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer.

Authors:  Marjun P Duldulao; Wendy Lee; Rebecca A Nelson; Joyce Ho; Maithao Le; Zhenbin Chen; Wenyan Li; Joseph Kim; Julio Garcia-Aguilar
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

9.  Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.

Authors:  Matthew R G Taylor; Dobromir Slavov; Kurt Humphrey; Lan Zhao; Jennifer Cockroft; Xiao Zhu; Philip Lavori; Michael R Bristow; Luisa Mestroni; Laura C Lazzeroni
Journal:  Pharmacogenet Genomics       Date:  2009-01       Impact factor: 2.089

Review 10.  High-risk childhood acute lymphoblastic leukemia.

Authors:  Deepa Bhojwani; Scott C Howard; Ching-Hon Pui
Journal:  Clin Lymphoma Myeloma       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.